We are testing whether zongertinib (BI 1810631) can improve outcomes for patients with advanced non-small cell lung cancer with HER2 mutations compared to standard treatment options.
Health conditions and diseases that the clinical trial is designed to study and treat.
Non-small cell lung cancer (NSCLC) is a type of lung cancer that includes several subtypes, primarily adenocarcinoma and squamous cell carcinoma. It is characterized by uncontrolled cell growth in lung tissues, leading to symptoms such as persistent cough, chest pain, and difficulty breathing.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
